Midtrimester preterm prelabour rupture of membranes (PPROM): expectant management or amnioinfusion for improving perinatal outcomes (PPROMEXIL – III trial) by Augustinus S P van Teeffelen et al.
van Teeffelen et al. BMC Pregnancy and Childbirth 2014, 14:128
http://www.biomedcentral.com/1471-2393/14/128STUDY PROTOCOL Open AccessMidtrimester preterm prelabour rupture of
membranes (PPROM): expectant management or
amnioinfusion for improving perinatal outcomes
(PPROMEXIL – III trial)
Augustinus S P van Teeffelen1*, David P van der Ham2, Christine Willekes1, Salwan Al Nasiry1, Jan G Nijhuis1,
Sander van Kuijk4, Ewoud Schuyt3,5, Twan L M Mulder6, Maureen T M Franssen7, Dick Oepkes8, Fenna A R Jansen8,
Mallory D Woiski9, Mireille N Bekker9, Caroline J Bax10, Martina M Porath11, Monique W M de Laat3,
Ben W Mol3,12 and Eva Pajkrt3Abstract
Background: Babies born after midtrimester preterm prelabour rupture of membranes (PPROM) are at risk to
develop neonatal pulmonary hypoplasia. Perinatal mortality and morbidity after this complication is high.
Oligohydramnios in the midtrimester following PPROM is considered to cause a delay in lung development.
Repeated transabdominal amnioinfusion with the objective to alleviate oligohydramnios might prevent this
complication and might improve neonatal outcome.
Methods/Design: Women with PPROM and persisting oligohydramnios between 16 and 24 weeks gestational age
will be asked to participate in a multi-centre randomised controlled trial. Intervention: random allocation to
(repeated) abdominal amnioinfusion (intervention) or expectant management (control). The primary outcome is
perinatal mortality. Secondary outcomes are lethal pulmonary hypoplasia, non-lethal pulmonary hypoplasia, survival
till discharge from NICU, neonatal mortality, chronic lung disease (CLD), number of days ventilatory support,
necrotizing enterocolitis (NEC), periventricular leucomalacia (PVL) more than grade I, severe intraventricular
hemorrhage (IVH) more than grade II, proven neonatal sepsis, gestational age at delivery, time to delivery, indication
for delivery, successful amnioinfusion, placental abruption, cord prolapse, chorioamnionitis, fetal trauma due to
puncture. The study will be evaluated according to intention to treat. To show a decrease in perinatal mortality
from 70% to 35%, we need to randomise two groups of 28 women (two sided test, β-error 0.2 and α-error 0.05).
Discussion: This study will answer the question if (repeated) abdominal amnioinfusion after midtrimester PPROM
with associated oligohydramnios improves perinatal survival and prevents pulmonary hypoplasia and other
neonatal morbidities. Moreover, it will assess the risks associated with this procedure.
Trial registration: NTR3492 Dutch Trial Register (www.trialregister.nl).
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Preterm prelabour rupture of membranes (PPROM) before
or near the limit of viability is associated with high peri-
natal morbidity and mortality. Respiratory complications
are frequent after periviable PPROM, as well as sepsis, in-
traventricular haemorrhage, retinopathy and necrotising
enterocolitis (NEC). Among respiratory complications pul-
monary hypoplasia is an important cause of death. Other
respiratory complications consist of pneumonia, Infant re-
spiratory distress syndrome (IRDS) and bronchopulmonary
dysplasia (BPD).
PPROM before 26 weeks can delay lung development
and can cause pulmonary hypoplasia [1]. Pulmonary hypo-
plasia is a term to describe an altered pulmonary deve-
lopment characterised by a reduction in the number of
pulmonary alveoli or in bronchial branching. In fetal lung
development a critical interval, the canalicular phase, exists
between 16 and 28 weeks gestation. Gestational age at rup-
ture of membranes has been shown to be inversely related
to the risk of pulmonary hypoplasia.
Pulmonary hypoplasia results in severe respiratory failure
leading to early neonatal death, respiratory insufficiency
with pulmonary haemorrhage, bronchopulmonary dyspla-
sia, or sub-acute lung disease, or sometimes in mild transi-
ent respiratory disease [2]. Perinatal mortality approximates
70% in most series (55-100%) [3].
In a review of 11 studies on midtrimester PPROM, the
reported incidence of pulmonary hypoplasia secondary to
midtrimester PPROM ranged widely from 1% to 48% [4].
A review of 6 studies on PPROM before 24 weeks reported
an incidence of pulmonary hypoplasia of 19% (n = 120) [5].
These percentages do not represent the true natural his-
tory, given the limitations of these reviews, summarising
only retrospective cohorts from tertiary care centres. The
wide range in prevalence is partly explained by the absence
of uniform pathological and clinical definitions. Histo-
logical findings form the basis of the diagnosis pulmonary
hypoplasia, however complete autopsy data were often not
available [2]. An international recognized definition of pul-
monary hypoplasia is lacking, and it rather is a diagnosis
by exclusion [6]. Congenital pneumonia, infant respiratory
distress syndrome (IRDS) and pulmonary hypoplasia some-
times occur simultaneously, and have overlapping symp-
toms [1]. Moreover, there were methodological problems
in the reviews, such as differences in follow-up and lack of
blinded assessment of the endpoints.
Pregnancies complicated by midtrimester PPROM are
associated with high immediate and long-term costs.
These are caused by extended maternal hospital ad-
missions, increased incidence of premature delivery, and
frequent neonatal complications hereafter requiring
NICU-admission.
Amnioinfusion might improve fetal outcome by pre-
venting pulmonary hypoplasia, by preventing neurologicalcomplications, increasing time to delivery interval, and
improving fetal biophysical profile through prevention of
umbilical cord compression. It also might prevent fetal de-
formity [7]. Porat et al. [8] reviewed serial transabdominal
amnioinfusion and meta-analysed observational as wel as
randomised studies. The only two included randomised
studies however were on women with PPROM between
24 and 34 weeks whereas the critical interval for deve-
lopment of pulmonary hypoplasia, the canalicular phase,
exists between 16 and 28 weeks gestation. One quasi-
randomised study included women with PPROM be-
fore 24 weeks. There were two observational studies on
PPROM before 24 weeks. Recently, Roberts et al. [9] pub-
lished the only randomized trial on PPROM between 16
and 24 weeks. They found no difference in the primary
outcome (perinatal mortality 19/28 vs. 19/28; RR 1.0; 95%
CI0.70-1.43), maternal or neonatal morbidity. The ob-
served difference in long term outcome (4/28 morbidity
free survival at 2 years in the treatment group vs 0/28 in
the group with expectant management) justifies further
study.
Adverse events after antepartum transabdominal am-
nioinfusion have been reported. It is not clear which ad-
verse effects are to be attributed to the procedure rather
than to the condition of PPROM and oligohydramnios,
since conservatively managed PPROM carries high risks
inherent to the condition itself [7]. Waters and Mercer re-
cently reviewed perinatal mortality after conservatively
managed PPROM <26 weeks [5]. Meta-analysis of 6 stu-
dies (n = 275) shows a perinatal mortality of 54%, (if
restricted to <24 weeks this incidence is 57%). These data
are biased by the fact that patients not amenable to con-
tinued expectant management were often excluded (i.e.
stillbirths, pregnancy terminations), and therefore survival
is likely to be overestimated.
A retrospective analysis by Van der Heijden et al. on
outcome after PPROM in three tertiary centres in The
Netherlands was recently published [10]. Their study in-
cluded 14 multiple pregnancies. When these were ex-
cluded, in 164 singleton pregnancies with PROM before
24 weeks there was a perinatal mortality of 71% Of all
mortality 38% occurred in the neonatal period (data not
published). It can be questioned whether all pregnancies
with PROM <24 weeks have been referred. Lethal pul-
monary hypoplasia was documented in only 16 cases
(10%), which is probably an underestimation as discussed
before (personal communication by Van der Heijden).
In summary, midtrimester PPROM is associated with a
high incidence of perinatal mortality, pulmonary hypopla-
sia and other neonatal complications. Exact incidences are
difficult to obtain because of selection biases, probably
leading to substantial underreporting. Diagnosis of pul-
monary hypoplasia is difficult due to overlapping symp-
toms and absence of uniform definitions. Amnioinfusion
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incorporate this seemingly safe procedure in daily practice.
Therefore we believe there is the need to assess the role of
amnioinfusion after midtrimester PPROM. We are cur-
rently conducting a multicentre randomised controlled
clinical trial. This study is conducted within the Dutch
Obstetric Consortium, a collaborative effort of obstetric
clinics in The Netherlands to perform clinical trials. Seven




The primary aim of this study is to evaluate the effec-
tiveness of amnioinfusion compared to expectant ma-
nagement for relieving oligohydramnios in women with
midtrimester PPROM occurring before 24 weeks gesta-
tional age in reducing perinatal mortality and neonatal
morbidities.
Participants/eligibility criteria
All women with a singleton pregnancy who are first di-
agnosed between 16 and 24 weeks gestational age with
oligohydramnios secondary to PPROM, at least 72 hours
after PPROM was diagnosed, but no longer than 21 days
after the diagnosis of oligohydramnios, are eligible for
the trial. Women with oligohydramnios secondary to
iatrogenic PPROM are also eligible.
We will exclude women with signs of uterine contrac-
tions, (8 uterine contractions per hour) intrauterine infec-
tion (temperature > 38°C plus fetal tachycardia or uterine
tenderness or foul/purulent amniotic fluid), a pregnancy
complication (hypertension, HELLP syndrome, preeclam-
psia or other) in which there is a need for termination of
pregnancy, placental or major structural fetal anomalies,
signs of cervical incompetence (visible cervical dilatation
or a cervical length of <25 mm), and women whose child
has signs of fetal distress (abnormal biophysical profile).
Procedures, recruitment, randomisation and collection of
data
The research nurse and/or the staff of participating hos-
pitals will identify eligible women. Prior to randomisa-
tion, in all patients amniotic fluid loss will be objectified
by sterile speculum examination for visible fluid loss
from the cervical os, by a nitrazine- and/or ferning test.
Speculum examination will be performed to exclude
signs of cervical incompetence (visible dilatation). Here-
after patients will undergo an ultrasound examination to
determine the single deepest pocket (SDP) of amniotic
fluid and to exclude placental and or fetal structural
anomalies. At this time ultrasound measurements used
in the prediction of pulmonary hypoplasia - TC/AC
(thoracic circumference/abdominal circumference), TC/FL (thoracic circumference/femur length), Doppler
measurement of pulmonary artery proximal branch peak
systolic velocity, 3D lung volume measurement -, will be
performed by specialized personnel.
If oligohydramnios is present (SDP < 2 cm) patients
will be counselled for the study. Randomisation, will
take place immediately after informed consent has
been obtained, at least 72 hours after diagnosis of
PPROM. See also Figure 1.
Randomisation will be performed, using an internet-
based procedure, with the use of a permuted-block
design, after informed consent and baseline data have
been entered in a web-based database system.
Treatment allocation will obviously have to be un-
blinded for patients and clinicians and sonographers,
and the personnel performing the ultrasound investi-
gations, however, allocation will remain blinded for
paediatricians, pathologists and/or radiologists who
are assessing outcomes.
All data are collected, coded and processed with
adequate precautions to ensure patient confidentia-
lity. The investigators will publish the results of the
study in a peer reviewed medical journal as soon as
appropriate.
Interventions
The intervention being evaluated is trans-abdominal
amnioinfusion. After sterile preparation of the abdo-
men, a pocket of fluid is identified by ultrasound guid-
ance after which a needle is advanced into this pocket.
After insuring proper placement by withdrawing a small
amount of fluid, the desired volume of fluid (Ringers
lactate), defined by the number of weeks of gestational
age times 10 millilitres, is infused manually. This pro-
cedure is repeated on a weekly basis if oligohydramnios
re-occurs or persists.
If, after initial amnioinfusion, uterine contractions and
signs of infection have been excluded, discharge is op-
tional. Fluid retention will be assessed by measurement of
SDP 48–72 hours after first amnioinfusion. Five to seven
days after initial amnioinfusion, SDP is reassessed, as well
as infection parameters (white cell count and CRP).
Measurement of TC/AC, TC/FL, Doppler measurement,
3D lung volume measurement, will be performed by spe-
cialised personnel. If persisting or re-occurring oligohy-
dramnios is diagnosed, amnioinfusion will be repeated.
The same procedure will be repeated on a weekly basis
until 28 weeks’ gestation.
Patients randomised to expectant management will
undergo the same clinical and ultrasound examination
bi-weekly (once a week measurement of SDP, TC/AC,
TC/FL, Doppler, 3D lung volume, infection parameters,
and on the second weekly visit assessment of fetal well-
being and measurement of SDP). These patients can,
Figure 1 Flowchart PPROMEXIL-III trial.
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excluded, at the discretion of the local physician, be dis-
charged as well (Figure 1). All discharged patients will be
instructed to take their temperature twice daily and contact
the hospital in case of fever (temperature > 37.8°C, rectally
measured) or suspected infection. Patients with midtrime-
ster PPROM are usually hospitalised after 24 weeks in a
tertiary centre.
Use of co-intervention
Corticosteroids are given according to local protocol,
usage will be recorded in the case report form. All pa-
tients will receive treatment with antibiotics (Erythro-
mycin orally 250 mg 4 times per day for ten days).
Patients may stop participating in the study at any
time for any reason if they wish to do so without any
consequences. The investigator can decide to withdraw a
subject from the study for urgent medical reasons.Study parameters/endpoints
We will compare two groups:
1) Amnioinfusion for midtrimester PPROM with
oligohydramnios, and
2) Expectant management for midtrimester PPROM
with oligohydramnios.
The primary outcome measure will be perinatal mor-
tality, defined as intrauterine death, intrapartum death
or neonatal death in the first 28 days of life.
Secondary outcomes are:
 Gestational age at delivery.
 Time from membrane rupture to delivery.
 Indication for delivery.
 Successful amnioinfusion (defined as retention of
infused fluid as defined by a single deepest pocket of
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 Chorioamnionitis, (defined as fever before or during
labour as a temperature greater than 37.5°C on two
occasion more than one hour apart or a
temperature > 38.0°C with either uterine tenderness
(or contractions), leucocytosis, maternal or fetal
tachycardia, or a foul-smelling vaginal discharge in
absence of any other cause of hyperpyrexia).
 Fetal trauma due to puncture.
 Maternal length of stay in hospital.
Occurrence of secondary outcomes placental abrup-
tion, cord prolapse, chorioamnionitis and fetal trauma
will be related to the number of amnioinfusions that
have been performed.
Neonatal endpoints:
 Lethal pulmonary hypoplasia diagnosed according to
radiological, clinical and pathological criteria.
Pathological criteria are based on radial alveolar
counts and lung/body weight ratios according to
Askenazi and Perlman [11], when radial alveolar
counts cannot be obtained, criteria by Wigglesworth
et al. will be used [12]. Clinical criteria used to
diagnose lethal pulmonary hypoplasia are:
immediate onset of severe respiratory insufficiency
after birth, small lung capacity and requirement of
high ventilatory pressures in the absence of
obstruction or atelectasis. Radiological criteria
according to Leonidas will be used [13].
 Non-lethal pulmonary hypoplasia diagnosed using
same clinical and radiological criteria in surviving
neonates.
 Survival till discharge from NICU.
 Neonatal mortality, defined as neonatal death in the
first 28 days of life.
 Chronic lung disease (CLD), CLD defined as oxygen
dependency at 28 days of life [14].
 Number of days on ventilatory support.
 Length of stay in hospital.
 Necrotising enterocolitis (NEC) more than stage I
and defined according to the criteria of
Bell et al. [15].
 Periventricular leukomalacia (PVL) more than grade
I and defined according to the classification
described by De Vries et al. [16].
 Severe intraventricular hemorrhage (IVH) more
than grade II and defined according to the criteria of
Papile et al. [17].
 Proven neonatal sepsis defined as (1) Positive blood
culture taken at birth or (2) within 72 hours two ormore symptoms of infection (apnea, temperature
instability, lethargy, feeding, intolerance, respiratory
distress, hemodynamic instability) plus one of three
items: (a) positive blood culture (culture proven
sepsis); (b) CRP > 20 (suspicion sepsis); (c) positive
surface cultures of a known virulent pathogen
(suspicion sepsis).
The neonatal endpoints will be defined by two neona-
tologists. The status of these endpoints will be evaluated
at six months corrected age. Additional application for
long-term follow-up of children (2 and 5 years) and
mothers will be performed.
Safety reporting
This study has been approved by the ethics committee
(METC) of the Academic Medical Centre Amsterdam
and by the boards of management of all participating
hospitals.
In accordance with the National Medical Research Act
(WMO, Section 10, Subsection 1), the investigator will
inform the subjects and the reviewing accredited METC
in case it appears that the disadvantages of participation
may be significantly greater than was foreseen in the
research proposal. All observed or volunteered adverse
events, regardless of suspected causal relationship to the
intervention, will be recorded.
An adverse event (AE) is defined as an event after
which the intervention has to be stopped. Reasons for
discontinuation are placental abruption, cord prolapse,
chorioamnionitis, fetal loss, fetal trauma due to punc-
ture, premature labour and delivery.
A serious adverse event (SAE) is defined as fetal or ma-
ternal death or illness necessitating IC or CCU treatment.
All SAEs will be reported to the accredited METC that ap-
proved the protocol, according to the requirements of that
METC. In addition to the expedited reporting of SAE’s,
the principal investigator will submit, once a year through-
out the clinical trial, a safety report to the accredited
METC.
A Data Safety Monitoring Board (DSMB) will be estab-
lished prior to start of the trial.
Sample size calculation
A sample size calculation was based on an expected rate
of perinatal mortality of 70% with expectant manage-
ment, to be reduced to 35% with amnioinfusion. Using a
two-sided test, with a β-error of 0.20 and an α-error of
0.05 a sample size of 56 women (28 in each arm) is
needed.
An interim analysis is planned after the follow up data
of the first 28 women that have been included. The
analysis will be performed using the O’Brien-Flemming
alpha spending function meaning a nominal P value of
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significance [16]. If there is a significant difference in the
primary outcome the trial will be stopped.
Statistical analysis
The analysis of the randomised clinical trial will be per-
formed on an intention-to-treat principle. The differences
between the amnioinfusion and expectant management
will be assessed by calculating the ratio of the outcome
rates in the two groups. Hence, the measure of association
is a relative risk (RR) with a 95% confidence interval (CI),
calculated using a log-binomial model. Time to delivery
will be evaluated by Cox proportional hazard analysis,
Kaplan-Meier estimates and tested with a log rank test.
In case of equivalence between outcomes, the analysis
will be repeated on an “as-treated” basis. Subsequently,
primary and secondary outcomes will be described in a
subgroup of women with successful amnioinfusion (re-
tention of infused fluid first 48 hours). All analyses will
be adjusted for the fact that an interim analysis will be
performed using the O’Brien-Flemming alpha spending
function [18]. Consequently, a nominal P value of less
than 0.049 will be considered to indicate statistical
significance.
Discussion
There are signs that pregnancies complicated by oligohy-
dramnios after midtrimester PPROM might benefit from
amnioinfusion. However, currently there is insufficient
evidence to recommend this procedure. The benefits
might be increased neonatal survival and decreased pul-
monary complications, especially pulmonary hypoplasia.
Potential harms include placental abruption, premature
labour and delivery, cord prolapse, chorioamnionitis,
fetal loss, fetal trauma due to puncture. Of these, only
the last mentioned is not a known potential complica-
tion of the underlying condition itself as well (midtri-
mester PPROM). Expectant management indeed carries
these same risks. At present, there is no evidence on
which a rational choice between expectant management
or therapeutic amnioifusion can be based.
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